Remote assessment for people with Parkinson's disease
PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's
This study is testing whether an online questionnaire and saliva samples can help people with Parkinson's disease learn about their genetics and find out if they might qualify for future clinical trials.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4800 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University College London Hospitals Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT06151002 on ClinicalTrials.gov |
What this trial studies
PD Frontline is an observational study aimed at preparing individuals with Parkinson's disease for participation in clinical trials. Participants complete an online questionnaire and receive a saliva collection kit to provide samples for genetic testing of the GBA1 and LRRK2 genes, which are associated with Parkinson's disease. The study seeks to identify potential candidates for gene-targeted trials and keep participants informed about relevant research opportunities based on their genetic results.
Who should consider this trial
Good fit: Ideal candidates are individuals with a formal diagnosis of Parkinson's disease who do not carry a GBA variant.
Not a fit: Patients with a confirmed GBA variant or those with other neurological disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the recruitment of patients for targeted therapies in Parkinson's disease.
How similar studies have performed: Other studies focusing on genetic testing in Parkinson's disease have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Formal diagnosis of Parkinson Disease Exclusion Criteria: * Confirmation that the individual carries a GBA variant (GBA positive). These individuals will be referred to sister-study, RAPSODI. * History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration) * Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease. * Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).
Where this trial is running
London
- University College London (UCL) — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Orla Mitchell
- Email: pdfrontline@ucl.ac.uk
- Phone: 020 801 68413
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.